A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia (Q28263502)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia	scientific article

Statements

scholarly article

0 references

A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia (English)

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

author name string

Hsien-Yuan Lane

1

0 references

Ching-Hua Lin

2

0 references

Yu-Jhen Huang

3

0 references

Chun-Hui Liao

4

0 references

Yue-Cune Chang

5

0 references

Guochuan E Tsai

6

0 references

language of work or name

0 references

publication date

May 2010

0 references

The International Journal of Neuropsychopharmacology

0 references

13

0 references

4

0 references

451-60

0 references

Glycine transport inhibitors and the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Transport and metabolism of sarcosine in hypersarcosinemic and normal phenotypes

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Glycine N-methyltransferase affects the metabolism of aflatoxin B1 and blocks its carcinogenic effect

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

D-serine-induced nephrotoxicity: possible interaction with tyrosine metabolism

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

D-alanine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Gene knockout of glycine transporter 1: characterization of the behavioral phenotype

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Glutamatergic mechanisms in schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

sar: a genetic mouse model for human sarcosinemia generated by ethylnitrosourea mutagenesis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Cloning and mapping of the cDNA for human sarcosine dehydrogenase, a flavoenzyme defective in patients with sarcosinemia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

The glutamatergic dysfunction hypothesis for schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Models for longitudinal data: a generalized estimating equation approach

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Modulation of N-methyl-D-aspartate receptor function by glycine transport

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

In vivo characterization of changes in glycine levels induced by GlyT1 inhibitors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

Reversal of Phencyclidine-Induced Dopaminergic Dysregulation by N-Methyl-D-Aspartate Receptor/Glycine-site Agonists

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

21 January 2018

The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

7 January 2021

based on heuristic

inferred from DOI database lookup

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

7 January 2021

based on heuristic

inferred from DOI database lookup

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

7 January 2021

based on heuristic

inferred from DOI database lookup

Five-factor model of schizophrenia. Initial validation

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990939

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1017/S1461145709990939

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28263502&oldid=1970943476"